A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment-Reference-Cited by-同舟云学术

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Published:2013 Issue:5-6 Volume:35 Page:325-339
ISSN:1421-9824
Container-title:Dementia and Geriatric Cognitive Disorders
language:en
Short-container-title:Dement Geriatr Cogn Disord

Author:

Morimoto Bruce H.,Schmechel Don,Hirman Joe,Blackwell Andrew,Keith Julian,Gold Michael

Publisher

S. Karger AG

Subject

Psychiatry and Mental health,Cognitive Neuroscience,Geriatrics and Gerontology

Reference36 articles.

1. Activity-dependent neurotrophic factor (ADNF)

2. NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP)

3. A Novel Signaling Molecule for Neuropeptide Action: Activity-dependent Neuroprotective Protein

4. NAP protects against cyanide-related microtubule destruction

5. NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity;Journal of Molecular Neuroscience;2024-09-10

2. Disentangling tau: One protein, many therapeutic approaches;Neurotherapeutics;2024-01

3. Targets, trials and tribulations in Alzheimer therapeutics;European Journal of Pharmacology;2024-01

4. The evolution of Alzheimer’s disease therapies: A comprehensive review;Annals of Medical Science & Research;2024-01

5. Novel therapeutic approaches for targeting Alzheimer’s disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024